Cardiovascular

FDA warns of potentially fatal arrhythmias with azithromycin

On March 12, 2013, the U.S. Food and Drug Administration (FDA) strengthened the warning for QT interval prolongation and torsades de pointes, a potentially fatal heart rhythm, associated with azithromycin (Zithromax or Zmax). Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares